Risedronate 5 mg daily for two years prevents bone loss in late postmenopausal women with osteopenia

被引：0
|
作者：
不详
机构：
来源：
CALCIFIED TISSUE INTERNATIONAL | 2006年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S162 / S162
页数：1
相关论文
共 50 条
  • [41] Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study
    M. J. Välimäki
    K. Laitinen
    K. Laitinen
    A. Patronen
    H. Puolijoki
    H. Puolijoki
    J. Seppänen
    L. Pylkkänenand the Probone Study Group*
    [J]. Osteoporosis International, 2002, 13 : 937 - 947
  • [42] Treatment with 5 mg alendronate in postmenopausal women with low bone mass
    Moggia, S
    Sayegh, F
    Otero, A
    Man, Z
    [J]. RECENT RESEARCH IN GYNECOLOGICAL ENDOCRINOLOGY, 2001, : 225 - 226
  • [43] Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis
    Solling, A. S. Koldkjaer
    Harslof, T.
    Langdahl, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 (05) : 995 - 1002
  • [44] Estrogen prevents cortical bone loss in early postmenopausal women: A histomorphometric study.
    Brockstedt, H
    Kassem, M
    Eriksen, EF
    Bone, A
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : T596 - T596
  • [45] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Gu, Jie-mei
    Wang, Li
    Lin, Hua
    Chen, De-cai
    Tang, Hai
    Jin, Xiao-lan
    Xia, Wei-bo
    Hu, Yun-qiu
    Fu, Wen-zhen
    He, Jin-wei
    Zhang, Hao
    Wang, Chun
    Yue, Hua
    Hu, Wei-wei
    Liu, Yu-juan
    Zhang, Zhen-lin
    [J]. ACTA PHARMACOLOGICA SINICA, 2015, 36 (07) : 841 - 846
  • [46] Once-weekly oral ibandronate prevents bone loss in postmenopausal women.
    Tankó, LB
    Riis, BJ
    Felsenberg, D
    Czerwinski, E
    Burdeska, A
    Jonkanski, I
    Hughes, C
    Christiansen, C
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S89 - S89
  • [47] Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis
    A.S. Koldkjær Sølling
    T. Harsløf
    B. Langdahl
    [J]. Osteoporosis International, 2019, 30 : 995 - 1002
  • [48] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Jie-mei Gu
    Li Wang
    Hua Lin
    De-cai Chen
    Hai Tang
    Xiao-lan Jin
    Wei-bo Xia
    Yun-qiu Hu
    Wen-zhen Fu
    Jin-wei He
    Hao Zhang
    Chun Wang
    Hua Yue
    Wei-wei Hu
    Yu-juan Liu
    Zhen-lin Zhang
    [J]. Acta Pharmacologica Sinica, 2015, 36 : 841 - 846
  • [49] Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women
    Laura D. Bilek
    Nancy L. Waltman
    Joan M. Lappe
    Kevin A. Kupzyk
    Lynn R. Mack
    Diane M. Cullen
    Kris Berg
    Meghan Langel
    Melissa Meisinger
    Ashlee Portelli-Trinidad
    Molly Lang
    [J]. BMC Women's Health, 16
  • [50] Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women
    Bilek, Laura D.
    Waltman, Nancy L.
    Lappe, Joan M.
    Kupzyk, Kevin A.
    Mack, Lynn R.
    Cullen, Diane M.
    Berg, Kris
    Langel, Meghan
    Meisinger, Melissa
    Portelli-Trinidad, Ashlee
    Lang, Molly
    [J]. BMC WOMENS HEALTH, 2016, 16
12345